February 26, 2013

Press Release

Mitsubishi Tanabe Pharma Corporation

TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus
Application for Partial Change in Indications for Combination Therapy

Osaka, Japan, February 26, 2013—Mitsubishi Tanabe Pharma Corporation (President & Representative Director, CEO: Michihiro Tsuchiya) announced today the company submitted an application for partial change in indications for TENELIA® 20mg tablets (generic name: teneligliptin hydrobromide hydrate tablets), for the treatment of type 2 diabetes mellitus.

TENELIA® is a DPP-4 (dipeptidyl peptidase-4) inhibitor created by Mitsubishi Tanabe Pharma, and was launched in September 2012 by Mitsubishi Tanabe Pharma and Daiichi Sankyo through their strategic alliance to contribute to the treatment of diabetes in Japan. TENELIA®, with its potent and sustained action, has made it highly effective in lowering the postprandial blood glucose levels, as well as fasting blood glucose levels, with once-a-day administration.

Mitsubishi Tanabe Pharma recently performed clinical studies of combination therapy with biguanides, α-glucosidase inhibitors and rapid-acting insulin secretagogues, under the Guideline for the Clinical Evaluation of Oral Hypoglycemic Agents. Accordingly, the company submitted an application for partial change in indications aiming the indication “type 2 diabetes mellitus” following the successful outcome of these studies employing combinations with possible oral hypoglycemic agents.

By providing this new treatment option for type 2 diabetes mellitus, Mitsubishi Tanabe Pharma hopes to provide further support for patients who are combating this disease.

<Contact for Inquiries>
Corporate Communications Department
Phone: +81 6-6205-5211